Karyopharm Therapeutics Inc (KPTI)

[adtime]

Look at all the recent 13g

[adtime]

Moving up on heavy volume with catalysts

[adtime]

I like this name

$KPTI

[Fibanotch]

need to dig a little deeper

[stock1ace1]

Latest news on clinical hold wasn't a good sign to me thoughts ?

[Fibanotch]

big move a commin

[venturecapp]

Looking Ahead To The Karyopharm Therapeutics MM Data http://marketexclusive.com/looking-ahead-karyopharm-therapeutics-inc-nasdaqkpti-mm-data/26008/?icd1

[ClearlyStocks]

KPTI hit $10.24 but still holding strong. Might go again this week. But play cautiously and don't forget your stops

[stockdawg44]

Nice one CS! keeps gaining momo......KPTI

[TheKobra]

What s your target?

[ClearlyStocks]

KPTI $10.21

[TheKobra]

Strong reaction today. Impressive.

[ClearlyStocks]

KPTI $9.79

[ClearlyStocks]

KPTI $9.65 boom!

[ClearlyStocks]

KPTI $9.50 about to pop

[ClearlyStocks]

KPTI $9.45

[ClearlyStocks]

KPTI $9.20 from $7.20

[TheKobra]

Ane news?

[ClearlyStocks]

$8.17

[ClearlyStocks]

$7.82

[ClearlyStocks]

$7.74

[ClearlyStocks]

$7.62

[ClearlyStocks]

$7.20s long

[remind2]

KPTI: FDA grants Orphan Drug Status. Treatment of soft tissue sarcoma


Posted on gov. site.

Not on news wires yet.

Major short squeeze on tap

[Pennyslayer02]

Here we go looking like we found bottom

[girlfriend]

You were right……the stock exploded……to the downside.

[Juice Newton]

I forgot to mention

I forgot to mention that there could be back to back catalysts in ASCO (May 29-June 3) and the European Hematology Association Conference June 11-14, 2015. If both of these conferences set off buying, it could be sustained over the course of a few weeks. Under the best case scenario, the demand could be very high while the supply is very low.

Speaking of Europe, let's go ahead and mention that they have a wholly owned European subsidiary to deal with trials and the approval process over there.

Ok, sorry for pumping, but I just wanted to let people know why I think this stock is about to get ridiculous.

[Juice Newton]

I believe this stock is primed to explode

I guess you can call this pumping, but let me just lay out some facts that lead me to believe that KPTI is about to shoot up dramatically like it did this time last year.

It's a low float, only 20 million shares. It's been beaten down by shorts over the past few months to near 52 week lows. The amount of shares short is currently sitting at a whopping 34% of float with 9-10 days to cover, according to Yahoo. The stock price is wound very tightly right now. All this leads me to believe that any good news would be a the catalyst for an explosion. It could very well be a repeat of last year where the price shot up 80% in one day. Why did it shoot up last year? They had really good results reported at ASCO 2014. Well, ASCO 2015 is coming up next weekend.

Last year the price went back down, likely because shorts jumped all over a stock that shot up 80% in one day. I doubt that anyone who can read a chart would chase the stock with that information in mind, so it might be 50-80% over the course of a few days. Actually, it might not matter if a new buyer knows what happened last year. The float and daily volume are so low that there might not be anything they can do about it if demand is high. Shorts will have to start covering after some moderate increase in price. This stock can easily squeeze them into buying quite high.

If you get in this week near 52 week lows, you could easily see a huge gain the next week, maybe near 52 week highs. Ok, so that's short term picture.

For the long term, this company has everything a clinical stage biotech needs to succeed. It has cash in the bank to last until 2018. Couple this with insider buys in the past few months (anticipating ASCO) and I think current holders are safe from further dilution in the near future. The science is great. They are the first company with a viable XPO1 inhibitor. It has no known adverse side effects and preliminary tests suggests that it does what it is supposed to do. Selinexor is in multiple Phase 2 trials for multiple indications right now, data of which will be presented at ASCO next weekend. I think over the next 3-5 years the enterprise value will at least double. I can't guess at the market cap over that time, but many analysts have 2015 price targets of $58-60 per share, more than 100% upside from today. Downside potential from here is, what, maybe a buck or two a share?

So there's my sales pitch. Get in this week at around $26/share and see huge returns soon after, or buy and hold for a ten bagger well within 5 years.

[Dspetry]

moving along nicely....

Karyopharm Therapeutics announces the issuance of a U.S. Patent for Selinexor - KPTI - 4-16-15

Co announced the issuance of U.S. Patent No. 8,999,996 entitled "Hydrazide Containing Nuclear Transport Modulators and Uses Thereof." This patent, which will expire in 2032 absent any patent term extensions, covers the composition-of-matter of Karyopharm's lead product candidate, selinexor (KPT-330), a first-in-class, oral SINE compound, as well as certain other compositions and related methods.

[Dspetry]

Insider K. Weg buys 5K @ $29.55 on 4/2/15

Somethings up...

http://insideri.com/1503802_000120919115032717_0001209191-15-032717

[Dspetry]

NEWTON, Mass., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that Nature Neuroscience published data showing Karyopharm's first-in-class oral Selective Inhibitor of Nuclear Export, or SINE(TM), compounds reduce the progression of multiple sclerosis (MS) in preclinical models.

http://www.fiercebiotechresearch.com/press-releases/nature-neuroscience-publishes-data-demonstrating-potential-therapeutic-bene

[kugel]

Love talking to myself only trouble is i quit listening. Good to see some blue sky's!!

[kugel]

OMG a lot of interest here..

[stocktrademan]

$KPTI DD Notes ~ http://www.ddnotesmaker.com/KPTI

bullish
cci(50) crosses 100 upwards
http://stockcharts.com/school/doku.php?st=cci&id=chart_school:technical_indicators:commodity_channel_index_cci
bull flag breakout

$KPTI recent news/filings

## source: finance.yahoo.com

Thu, 30 Oct 2014 12:00:00 GMT ~ Karyopharm to Report Third Quarter 2014 Financial Results on November 10, 2014

[GlobeNewswire] - NEWTON, Mass. -- Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company today announced it will report third quarter 2014 financial results on Monday, November 10, 2014. Karyopharm's management ...

read full: http://finance.yahoo.com/news/karyopharm-report-third-quarter-2014-120000529.html
*********************************************************

Mon, 27 Oct 2014 12:12:52 GMT ~ Karyopharm Expands Global Presence With European Subsidiary

[at noodls] - Experienced International Clinical Operations Executive, Ran Frenkel, Appointed Executive Vice President, Worldwide Clinical Development NEWTON, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics ...

read full: http://www.noodls.com/view/437F747CF46EA4AFD00AEEA755A51D83D7D4B2A1
*********************************************************

Mon, 27 Oct 2014 12:00:00 GMT ~ Karyopharm Expands Global Presence With European Subsidiary

[GlobeNewswire] - NEWTON, Mass. -- Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, announced today that it has expanded its operational footprint with a wholly-owned European subsidiary and appointed ...

read full: http://finance.yahoo.com/news/karyopharm-expands-global-presence-european-120000199.html
*********************************************************

Fri, 24 Oct 2014 10:41:26 GMT ~ Why Karyopharm Therapeutics (KPTI) Stock Might be a Great Pick


read full: http://finance.yahoo.com/news/why-karyopharm-therapeutics-kpti-stock-104126511.html
*********************************************************

Mon, 20 Oct 2014 12:35:39 GMT ~ Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential


read full: http://247wallst.com/healthcare-business/2014/10/20/merrill-lynchs-5-destroyed-biotech-stocks-with-100-or-more-upside-potential/
*********************************************************


$KPTI charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$KPTI company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/KPTI/company-info
Ticker: $KPTI
OTC Market Place: Not Available
CIK code: not found
Company name: Karyopharm Therapeutics Inc.
Incorporated In:


$KPTI share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$KPTI extra dd links

Company name: Karyopharm Therapeutics Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=KPTI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=KPTI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=KPTI+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/KPTI/news - http://finance.yahoo.com/q/h?s=KPTI+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/KPTI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/KPTI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=KPTI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/KPTI
DTCC (dtcc.com): http://search2.dtcc.com/?q=Karyopharm+Therapeutics+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Karyopharm+Therapeutics+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Karyopharm+Therapeutics+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/KPTI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/KPTI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/KPTI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=KPTI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=KPTI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/KPTI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=KPTI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=KPTI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=KPTI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=KPTI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=KPTI+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/KPTI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=KPTI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/KPTI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=KPTI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/KPTI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/KPTI/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/KPTI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/KPTI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/KPTI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=KPTI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=KPTI



$KPTI DD Notes ~ http://www.ddnotesmaker.com/KPTI

[ClayTrader]

* * $KTPI Video Chart 6-13-14 * *

Link to Video - click here to watch the technical chart video

[mlkrborn]

Karyopharm Therapeutics presents clinical data on Selinexor (KPT-330) in colorectal cancer from ongoing Phase 1 study and preclinical data on novel PAK4 inhibitors at American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium; Data demonstrate preliminary evidence of anti-tumor activity of oral selinexor in colorectal cancer patients (KPTI) :

Data Demonstrate Preliminary Evidence of Anti-Tumor Activity of Oral Selinexor in Colorectal Cancer Patients
Potential Anti-Proliferative Activity of Novel PAK4 Inhibitor Seen in Preclinical Pancreatic Cancer Model

Co announced data from two poster presentations at the American Society of Clinical Oncology (TATD) 2014 Gastrointestinal (:GI) Cancers Symposium that took place January 16-18 in San Francisco, California.

The data presented included an update (as of December 16, 2013) from the ongoing Phase 1 study of oral Selinexor in solid tumors that show preliminary evidence of antitumor activity in metastatic colorectal cancer (:CRC) patients. Additionally, data were presented on novel, oral p21-activated kinase 4 (PAK4) inhibitors that show anti-proliferative activity and tolerability in a preclinical pancreatic cancer model.

"We are very pleased with these preliminary results showing that single agent oral Selinexor has the potential to provide disease control in a subset of patients with heavily pretreated CRC. We are currently continuing our Phase 1 dose expansion cohorts and expect to report more data at the annual ASCO conference in June," stated Sharon Shacham, Ph.D., founder, Chief Scientific Officer and President of Karyopharm. "In addition, the preliminary preclinical data on our compounds that selectively inhibit PAK4 support our continued development of these potential therapies towards first-in-human studies."

8:35 am Hemispherx Biopharma analysis of new data on protection from pulmonary damage associated with infection by highly pathogenic influenza virus (HEB) :

Co announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21, 2014 at the Keystone Symposia Conference on Pathogenesis of Respiratory Viruses entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus (H5N1) by Low Dose Natural Human IFN-a Administered to the Buccal Mucosa." This presentation is a collaborative project conducted at Viroclinics, Rotterdam, an internationally recognized research entity for the study of both seasonal and pandemic influenza viruses. The biohazard facilities are directed by Prof. Albert D.M.E. Osterhaus, an internationally known virologist specializing in the study of pandemic influenza.
Thus, both H5N1 influenza virus (the subject of collaboration with the Osterhaus group) and H7N9 influenza virus (the subject of ongoing collaboration with Prof. J. Richt's group at the Center of Excellence for Emerging and Zoonotic Animal Diseases (:CEEZAD), Kansas State University (please see Expert Review of Anti-infective Therapy (online edition, pages 1-5, 2014) are susceptible to Alferon N treatment in various model systems.
Both H5N1 influenza virus and H7N9 influenza virus have recently lead to an increased incidence of clinical disease in various parts of the world.
The new study shows the importance of the interferon induced pathways in controlling influenza viral infection. No deaths were observed in individuals with the wildtype genotype, compared to a 33% mortality rate in patients with the dysfunctional interferon pathway genotype.

[surf1944]

8:32AM Karyopharm Therapeutics receives Award of grant from National Multiple Sclerosis Society to further develop selective inhibitors of nuclear export compounds (KPTI) 22.73 : Co announces that it has been awarded a grant from the National Multiple Sclerosis Society through its affiliate, Fast Forward, to support research on the potential of SINE compounds in inflammatory models of disease, including MS. Finding ways to restore and protect the damaged nervous system is a key priority of the National MS Society's No Opportunity Wasted research campaign to ultimately eradicate MS. No further details were provided at this time.

[Gixene]

New board.